PT - JOURNAL ARTICLE AU - Lammi, Vilma AU - Nakanishi, Tomoko AU - Jones, Samuel E. AU - Andrews, Shea J. AU - Karjalainen, Juha AU - Cortés, Beatriz AU - O’Brien, Heath E. AU - Fulton-Howard, Brian E. AU - Haapaniemi, Hele H. AU - Schmidt, Axel AU - Mitchell, Ruth E. AU - Mousas, Abdou AU - Mangino, Massimo AU - Huerta-Chagoya, Alicia AU - Sinnott-Armstrong, Nasa AU - Cirulli, Elizabeth T. AU - Vaudel, Marc AU - Kwong, Alex S.F. AU - Maiti, Amit K. AU - Marttila, Minttu AU - Batini, Chiara AU - Minnai, Francesca AU - Dearman, Anna R. AU - Warmerdam, C.A. Robert AU - Sequeros, Celia B. AU - Winkler, Thomas W. AU - Jordan, Daniel M. AU - Guare, Lindsay AU - Vergasova, Ekaterina AU - Marouli, Eirini AU - Striano, Pasquale AU - Zainulabid, Ummu Afeera AU - Kumar, Ashutosh AU - Ahmad, Hajar Fauzan AU - Edahiro, Ryuya AU - Azekawa, Shuhei AU - Long COVID Host Genetics Initiative AU - FinnGen AU - DBDS Genomic Consortium AU - GEN-COVID Multicenter Study AU - Grzymski, Joseph J. AU - Ishii, Makoto AU - Okada, Yukinori AU - Beckmann, Noam D. AU - Kumari, Meena AU - Wagner, Ralf AU - Heid, Iris M. AU - John, Catherine AU - Short, Patrick J. AU - Magnus, Per AU - Banasik, Karina AU - Geller, Frank AU - Franke, Lude H. AU - Rakitko, Alexander AU - Duncan, Emma L. AU - Renieri, Alessandra AU - Tsilidis, Konstantinos K. AU - de Cid, Rafael AU - Niavarani, Ahmadreza AU - Tusié-Luna, Teresa AU - Verma, Shefali S. AU - Smith, George Davey AU - Timpson, Nicholas J. AU - Daly, Mark J. AU - Ganna, Andrea AU - Schulte, Eva C. AU - Richards, J. Brent AU - Ludwig, Kerstin U. AU - Hultström, Michael AU - Zeberg, Hugo AU - Ollila, Hanna M. TI - Genome-wide Association Study of Long COVID AID - 10.1101/2023.06.29.23292056 DP - 2023 Jan 01 TA - medRxiv PG - 2023.06.29.23292056 4099 - http://medrxiv.org/content/early/2023/07/01/2023.06.29.23292056.short 4100 - http://medrxiv.org/content/early/2023/07/01/2023.06.29.23292056.full AB - Infections can lead to persistent or long-term symptoms and diseases such as shingles after varicella zoster, cancers after human papillomavirus, or rheumatic fever after streptococcal infections1, 2. Similarly, infection by SARS-CoV-2 can result in Long COVID, a condition characterized by symptoms of fatigue and pulmonary and cognitive dysfunction3–5. The biological mechanisms that contribute to the development of Long COVID remain to be clarified. We leveraged the COVID-19 Host Genetics Initiative6, 7 to perform a genome-wide association study for Long COVID including up to 6,450 Long COVID cases and 1,093,995 population controls from 24 studies across 16 countries. We identified the first genome-wide significant association for Long COVID at the FOXP4 locus. FOXP4 has been previously associated with COVID-19 severity6, lung function8, and cancers9, suggesting a broader role for lung function in the pathophysiology of Long COVID. While we identify COVID-19 severity as a causal risk factor for Long COVID, the impact of the genetic risk factor located in the FOXP4 locus could not be solely explained by its association to severe COVID-19. Our findings further support the role of pulmonary dysfunction and COVID-19 severity in the development of Long COVID.Competing Interest StatementElizabeth T Cirulli: AB, KMSB, SW, NLW, FT, ES, and ETC are employees of Helix. Andreas Dinkel: AD received a honorarium from Gilead Sciences. Vince Forgetta: VF is an employee of 5 Prime Sciences (www.5primesciences.com), which provides research services for biotech, pharma and venture capital companies for projects unrelated to this research. Anna L Guyatt: ALG has a funded research collaboration with Orion for collaborative research projects outside the submitted work. Thompson Hannah: Options in Sano Genetics Catherine John: CJ has a funded research collaboration with Orion for collaborative research projects outside the submitted work. Kerstin U Ludwig: KUL is co-founder and member of the scientific board of LAMPseq Diagnostics GmbH. Tomoko Nakanishi: TN has received speaking fee from Boehringer Ingelheim for talks unrelated to this research. Heath E O'Brien: Options in Sano Genetics Limited. J. Brent Richards: JBR's institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and Biogen for projects unrelated to this research. He is the CEO of 5 Prime Sciences (www.5primesciences.com), which provides research services for biotech, pharma and venture capital companies for projects unrelated to this research. Patrick J Short: Share holder in Sano Genetics Limited. Christoph D Spinner: CDS reports grants, personal fees from AstraZeneca, personal fees and non-financial support from BBraun Melsungen, personal fees from BioNtech, grants, personal fees and non-financial support from Gilead Sciences, grants and personal fees from Janssen-Cilag, personal fees from Eli Lilly, personal fees from Formycon, personal fees from Pfizer, personal fees from Roche, other from Apeiron, grants and personal fees from MSD, grants from Cepheid, personal fees from GSK, personal fees from Molecular partners, other from Eli Lilly, personal fees from SOBI during the conduct of the study; personal fees from AbbVie, personal fees from MSD, personal fees from Synairgen, grants and personal fees from ViiV Healthcare, outside the submitted work. Louise V Wain: Research collaborations and/or consultancy relationships with GSK, Genentech and Galapagos. All other authors have declared no competing interest.Funding StatementThis study is a global research collaboration funded by various parties. Detailed funding information for each contributing study/author is provided in the author information supplement (Acknowledgements field).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants provided informed consent to participate in the respective study, with recruitment and ethics following study-specific protocols approved by their respective Institutional Review Boards (Details are provided in Extended Table S2).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWe have made the results of these GWAS meta-analyses publicly available for variants passing post-meta-analysis filtering for minor allele frequency >=1% and effective sample size >1/3 of the maximum effective sample size for each meta-analysis. These can be accessed at LocusZoom, where the associations can be visually explored and the summary statistics exported for further scientific discovery. 1) Strict case definition (Long COVID after test-verified SARS-CoV-2 infection) vs broad control definition (population control) 2) Broad case definition (Long COVID after any SARS-CoV-2 infection) vs broad control definition 3) Strict case definition vs strict control definition (individuals that had SARS-CoV-2 but did not develop Long COVID) 4) Broad case definition vs strict control definition https://my.locuszoom.org/gwas/192226/ https://my.locuszoom.org/gwas/793752/ https://my.locuszoom.org/gwas/826733/ https://my.locuszoom.org/gwas/91854/